GPLB Green Planet Bioengineering Company Ltd (PK)

Green Planet Bioengineering CO., LTD. (OTCBB: GPLB) ("Green Planet" or the "Company"), a subsidiary of ONE Holdings, Corp. (OTCBB: ONEZ), a green process manufacturer of high quality health supplements, organic fertilizers and pesticides, announces the launch of two natural extracts called Resveratrol and 5-HTP.

The two new extracts are expected to contribute approximately $1.8 million to revenue during the third quarter with a $1 million in revenue already achieved since the extracts were launched. Two new customers recently signed long-term purchase agreements.

These two naturally occurring extracts which are mainly used as health supplements are commonly referred to as the 'Miracle Drug.' In co-operation with Fujian Traditional Chinese Medical College, Green Planet has successfully produced and launched a marketing campaign for the Polygonum Cuspidatum Extract (Resveratrol) and the Griffonia Seeds Extract (5-HTP).

Resveratrol is a powerful antioxidant that is produced by various plants to protect themselves against environmental stress. Perhaps the most notable producer of Resveratrol is the grapevine which produces large amounts of Resveratrol in the skin of grapes to protect against fungal diseases and sun damage. Recent studies indicate Resveratrol may have some therapeutic value in fighting various cancers. Resveratrol supplements come in various forms (mainly pills and tablets) and have become increasingly popular recently as more medical research studies have increased the supplements' exposure, and popular TV shows like "60 minutes" and "The Barbara Walters Special" have featured them.

5-HTP (full name -- 5-Hydroxytryptophan), a well-researched nutritional supplement, appears to have something to offer to the 'modern-age malady' sufferers, and 5-HTP is clinically claimed as a Prozac alternative due to its natural herbal character. In addition, it is found in clinical studies that it is effective for weight control, fibromyalgia and insomnia.

Green Planet filed two new extraction process patents in August 2009: one process extracts and prepares high purity Resveratrol from Polygonum Cuspidatum (Application No.: 2009103064095) and the other process extracts and prepares high purity 5-HTP from Griffonia Seeds (Application No.: 2009103064080).

"We are very excited to have launched our marketing efforts for these new extracts. Sales appear to show a raising trend, leading us to believe that these two new supplements will be highly profitable products with a promising future in the marketplace. We also anticipate expanding into more desirable and profitable green products," stated CEO of Green Planet Mr. Zhao.

For a full list of Green Planet's products please visit the Company's website: www.greenplanetbio.com

About Green Planet

Green Planet Bioengineering CO., LTD. ("Green Planet") (http://www.greenplanetbio.com) (OTCBB: GPLB), a subsidiary of ONE Holdings, Corp. (OTCBB: ONEZ) through its Chinese subsidiary, is a high-tech bioengineering enterprise that engages in research & development, production and sale of various extracts from tobacco leaves residue destined for health supplements and organic agricultural products. Green Planet is headquartered in Miami, FL with its main operation located in Sanming and Fuzhou, China. Since founded in 2005, Green Planet offers a full range of high quality bio-ecological products which include raw chemical materials such as CoQ10 and Solanesol, organic fertilizers and pesticides and organic health nutrients and supplements. The Company's unique position in the bioengineering industry comes from its R&D using patented cutting-edge methods to create abundant downstream products ranging from plant indigenous medicine, pharmaceutical intermediates to a long list of eco-friendly products.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). Green Planet Bioengineering, Co., Ltd. claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," or "anticipates," and do not reflect historical facts. Specific forward-looking statements contained in this press release include, but are not limited to: our successful integration of diversified growth companies, impact of the company's expansion plan, and new business development success, future financial results, development and acquisition of new product lines and services, the impact of competitive products or pricing from technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained herein involve risks and uncertainties that could cause actual results to differ materially from the expectations contained in any such forward-looking statements. These risks include, but are not limited to: failure to manage operating expenses or integrate new companies and/or technologies, each of which could have a material impact on our business, our financial results, and the company's stock price. These risks and other factors are detailed in the Company's regular filings with the U.S. Securities and Exchange Commission. Most of these factors are difficult to predict accurately and are generally beyond the Company's control. Forward-looking statements speak only as to the date they are made and Green Planet Bioengineering, Co., Ltd. does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

PROZAC is a registered trademark of Eli Lilly and Company

Contact: Investor Relations & Corporate Communications 877-544-2288 ir@greenplanetbio.com Company Contact: ONE Holdings Corporation Jeanne Chan Senior VP Tel. +877.544.2288 jchan@onehcorp.com